Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO) and Applied DNA Sciences (NASDAQ: APDN)
Allogene Therapeutics (ALLO) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Allogene Therapeutics, with a price target of $43.00. The company’s shares closed last Wednesday at $35.12. According to TipRanks.com, Burns is a 4-star analyst with an average return of 15.5% and a 44.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Allogene Therapeuti...